MYGN Stock Analysis: Buy, Sell, or Hold?
MYGN - Myriad Genetics Inc
$5.62
0.08 (1.44%)
▲
HOLD
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 23, 2026
22d
Get Alerted When MYGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: MYGN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: MYGN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: MYGN is currently trading at $5.62, which is considered oversold relative to its 30-day fair value range of $5.81 to $6.47. From a valuation perspective, the stock is trading at a discount (Forward PE: 81.6) compared to its historical average (96.0). Remarkably, the market is currently pricing in an annual earnings decline of 5.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, MYGN is in a strong downtrend. The price is currently testing key support at $5.46. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MYGN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $8.12 (+46.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, MYGN is in a strong downtrend. The price is currently testing key support at $5.46. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MYGN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $8.12 (+46.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$5.81 -
$6.47
Company Quality Score
54/100
(HOLD)
Options IV Signal
50th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
59.6%
Protect Your Profits
Holding MYGN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 50th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 46.6% below Wall St target ($8.12)
Fair Price Analysis
30-Day Fair Range
$5.81 -
$6.47
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$0.91
(16.2%)
Support & Resistance Levels
Support Level
$5.47
Resistance Level
$6.15
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
81.59
Wall Street Target
$8.12
(+46.6%)
Revenue Growth (YoY)
-3.6%
Profit Margin
-48.5%
Valuation Discount vs History
-5.3% cheaper
PE vs Historical
81.6 vs 96.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.3%
(market-implied from PE analysis)
1-Year Target
$5.25
(-5%)
2-Year Target
$4.97
(-10%)
3-Year Target
$4.71
(-15%)
3-Yr Target (if PE normalizes)
(PE: 82→96)
$5.54
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 81.6, Growth: 1641.0%)
$18.70
(+238%)
Base:
(SPY PE: 22.3, Growth: 1641.0%)
$5.11
(-8%)
Bear:
(PE: 19.0, Growth: 1641.0%)
$4.34
(-22%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 81.6 to 96.0
Stabilization Target:
$6.52
(+17.7%)
PE Expansion Potential:
+17.7%
Last updated: January 31, 2026 7:47 AM ET
Data refreshes hourly during market hours. Next update: 8:47 AM
Data refreshes hourly during market hours. Next update: 8:47 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MYGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$653 | 47 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 57 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
24 analysts |
$121 | 62 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
26 analysts |
$263 | 47 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$257 | 58 HOLD |
Advanced MYGN Option Strategies
Professional options setups generated by AI based on today's MYGN price and gamma walls.
